Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas
Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas
复制标题
DOI：
10.3109/09513590.2016.1147547
复制
发表时间：
2016-01-01
影响因子：
2
通讯作者：
Kimura, Tadashi
中科院分区：
文献类型：
--
作者：
Adachi, Kazushige;Takahashi, Kayo;Kimura, Tadashi
为了评估地诺孕素对卵巢子宫内膜异位瘤复发和腹腔镜手术后疼痛严重程度的影响，日本大阪的三个机构对 81 名患者进行了一项回顾性研究。 2012 年 6 月至 2014 年 8 月期间进行的卵巢子宫内膜异位症腹腔镜手术后，患者接受了至少 6 个月的随访。选择每天接受 2 mg 地诺孕素的患者和术后期待治疗的患者均被纳入其中。复发被定义为存在超过2厘米的子宫内膜瘤。使用视觉模拟量表（VAS）对盆腔疼痛的强度进行评分。评估两组的累积复发率和绝对VAS评分在基线与开始给药后6、12、18和24个月之间的变化。期待治疗组12个月和24个月时的复发率分别为16.5%和24.0%。地诺孕素治疗组未出现复发。地诺孕素组的 VAS 评分降低率显着高于期待治疗组。地诺孕素对卵巢子宫内膜异位症复发和腹腔镜手术后盆腔疼痛有效。
To assess the effect of dienogest on recurrence of ovarian endometriomas and severity of pain after laparoscopic surgery, a retrospective study of 81 patients was performed at three institutions in Osaka, Japan. Patients had a six-month minimum follow-up after laparoscopic surgery for ovarian endometriomas performed between June 2012 and August 2014. Patients who chose to receive 2 mg dienogest daily and those who were managed expectantly postoperatively were included. Recurrence was defined as the presence of endometriomas of more than 2 cm. A visual analog scale (VAS) was used to score the intensity of pelvic pain. The cumulative recurrence rate and absolute VAS score changes between the baseline and at 6, 12, 18 and 24 months after the start of administration were evaluated in both groups. The recurrence rate was 16.5% and 24.0% in the expectant management group at 12 and 24 months, respectively. No recurrences occurred in the dienogest treatment group. The rate of VAS score reduction was significantly higher in the dienogest than in the expectant management group. Dienogest is effective on the recurrence of ovarian endometrioma and relieving pelvic pain after laparoscopic surgery.